Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

South Korea: Supreme Court rules on inventive step

Sponsored by


Recently, the Korean Supreme Court made a key decision regarding how to read the prior art when making an inventive step determination (2013 Hu 2873 and 2880 (consolidated), January 14 2016).

In Korea, a broad range of prior art may be used to deny the inventive step of claims. For example, a prior art reference which discloses an incomplete invention or a prior art of which description is insufficient or even defective may qualify as prior art for the purpose of inventive step determination as long as an artisan may understand the technical content of the references. However, no precedent yet clearly addressed the situation when contradictory information is present within the same or different pieces of prior art. The Supreme Court of Korea answered this question for the first time in its recent decision to the pregabalin invalidation case.

Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid) is a blockbuster drug marketed under the brand name Lyrica by Pfizer which is used to treat epilepsy, neuropathic pain, fibromyalgia, and generalized anxiety disorder. In the pregabalin decision, the Supreme Court held that a prior art reference must be considered in its entirety and not just from a portion of description. The Court also held that when a different piece of prior art contradicts other pieces of prior art, they should all be considered together to determine inventiveness.

In this case, claim 1 at issue was "a pharmaceutical composition comprising pregabalin for treating pain". Generic companies filed an invalidation action against the Korean patent with this claim 1. In the first instance of this case, the Korean Intellectual Property Tribunal found that claim 1 was not inventive over the cited prior art. However, on appeal, the Patent Court acknowledged the inventiveness of claim 1. This decision was upheld by the Supreme Court. In the Supreme Court, the challengers made two primary arguments attacking the inventiveness of claim 1, one of which was about elevating the level of GABA (gamma-aminobutyric acid) in the brain.

From a portion of the prior art D1, it was disclosed that pregabalin increases the level of GABA in the brain. On the assumption that the convulsions decrease when GABA level in the brain is elevated, the prior art tested a group of compounds in vitro and in vivo to show that an activation of GAD (L-Glutamic acid decarboxylase), an enzyme which produces GABA, promotes prevention of seizure. However, this relationship between the activation of GAD and the increase of GABA or the increased prevention of seizure was not clear. For example, in case of a pregabalin, activation of GAD was low, but the potency was high. Additionally, there were other pieces of prior art which disclosed no or unclear correlation between the in vitro GAD activation and the increased level of GABA or anti-convulsion activity. In other words, disclosure of D1 that the "pregabalin increases GABA level" was not clear in view of the other parts of the same reference D1 and also disclosures of separate prior art references.

Under this circumstance, the Supreme Court ruled that it would have been not easy for a person having an ordinary skill in the art to conceive the claim 1 invention from the D1's disclosure about pregabalin's ability to increase the level of GABA, which the court believed to be ambiguous.

In the decision, the Court made it clear that "… to determine the inventiveness of an invention, the prior art should be considered in its entirety … not just from the portion of prior art …" The Court further addressed a seemingly new principle in Korea that "… when a different prior art is presented which is contradictory to the (portion of) prior art, then, this prior art reference must also be considered … when determining the inventive step".

This decision seems to be particularly important and useful in the field of life science and chemistry where often the contradictory results are reported in the same technical field in a rather short period of time. This Supreme Court decision is significant in that it made clear that the prior art should be considered as a whole, and in that it presented a new principle that the court must consider all the prior art including those contradictory to each other. Applicants and patent owners now may rely on this new decision to more effectively argue the inventiveness of their claimed subject matters in Korea.

Min Son

Partner, Hanol IP & Law


HANOL Intellectual Property & Law

6th Floor, 163, Yang Jae Cheon-Ro, Gang Nam-Gu

Seoul 06302, Republic of Korea

Tel: +82 2 942 1100

Fax: +82 2 942 2600

more from across site and ros bottom lb

More from across our site

Cyril Amarchand Mangaldas has hired former Anand & Anand partner Swati Sharma and hopes to compete with specialist IP firms
Rapporteur-Judge András Kupecz ruled that education and training weren’t legitimate reasons for a member of the public to access documents
Searches for comparison prior art will be a little easier, but practitioners will have to put more thought into claim construction and design patent titles
The Helsinki local division rejected AIM Sport’s request for a preliminary injunction in a dispute with rival Supponor
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
The FTC’s plans to scrutinise improperly listed Orange Book patents could make these listings more important in litigation, but firms should be looking at this anyway
Counsel at Debevoise & Plimpton explain how they helped food delivery business Grubhub avoid a preliminary injunction at the Court of Appeals for the Seventh Circuit
European lawyers tell Managing IP how the legal market is reacting to the first few months of the UPC and why cases are set to take off
The ban could be extended or cancelled, depending on whether Judge Pauline Newman cooperates with an investigation, the Judicial Council of the Federal Circuit stated
Sources say some China-based lawyers are prepared to take large pay cuts to join stable practices, but most firms are sceptical about new hires